Toronto, ON, March 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Ryerson researchers have a long history of successful collaborative R&D endeavors with Toronto Poly Clinic Inc. (a subsidiary of Tree of Knowledge International Corp. (TOKI) CSE: TOKI – OTC: TOKIF) and more recently with TOKI. The novel nano-technology collaborative research project is investigating new ways of delivering cannabinoid molecules to target regions in the body for cancer therapy and pain management. Ryerson researchers received the Health Canada license under the Cannabis Act and Regulations to start the project on March 6, 2020. TOKI is the sponsor and clinical collaborator for the project.
“This Health Canada approval of a research license opens the way for new investigations on developing nano-medicine and delivery methods with cannabinoids. Targeted treatments are essential for many cancer therapies and pain conditions and our project with Ryerson researchers can now work with medical cannabis for our treatment goals. This has been a great milestone for our research,” says Dr. Kevin Rod, the Chief Medical Advisor to TOKI.The Ryerson research team is extremely pleased with this Health Canada license approval to start working on this novel and exciting collaborative R&D initiative. They anticipate building upon the jointly-developed nano-medicine and ultrasound technology platforms to further advance the novel field of targeted cannabinoid drug delivery for cancer treatment and pain management.With its head office in Toronto, and operations in North York, Ontario, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at a GMP manufacturing facility and (3) Distribution and sale of hemp-based cannabidiol (“CBD”) products in the United States, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational studies on medical cannabis and from its ongoing direct patient experience. The Company has also developed and implemented MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Company is expanding its product line to include Health Canada approved Natural products for support of the immune system and general health and wellness during these challenging times of the Corona virus.Contact:Tree of Knowledge International Corp.Michael CaridiChairman/CEOmichael@tokicorp.com917.295.1374About Tree of KnowledgeWith its head office in Toronto, and operations in North York, Ontario and Spokane, Washington, TOKI currently has three primary business segments: (1) Multidisciplinary specialty pain clinics with a focus on the treatment of chronic pain, including controlled applications of medical cannabis in Canada, (2) Development of formulated products for therapeutic purposes and natural health product alternatives at a GMP manufacturing facility and (3) Distribution and sale of hemp-based cannabidiol (“CBD”) products in the United States, Canada, Europe, Brazil and Australia. Through its Toronto Poly Clinic, the Company has gleaned extensive expertise from being involved in one of the largest observational clinical trials on medical cannabis and from its ongoing direct patient experience. The Company has developed and implemented MCERP (Medical Cannabis Education, Research and Best Practice Platform) and MCORP (Medical Cannabis Opioid Reduction Program) with great success. Currently, the Company has research agreements with multiple universities for medical cannabis research and new medical grade products development. TOKI’s CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States. TOKI currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.Notice Regarding Forward Looking StatementsThis news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to future product format offerings. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company’s ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company’s annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Bay Street News